
Fulgent Genetics, Inc.: updates and filings
Price
$24.14
November 20, 2026Market cap $674M
What Ploutos Investor adds for Fulgent Genetics
Part of Ploutos Investor, €9.99 a month
- The full history: 12 fiscal years, from 2014
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has risen 35% since Nov 5, 2026, when the 10-Q these figures come from was filed ($18.66 then, $25.13 on Nov 18, 2026). The figures date from before that move.10-Q
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 5, 2026next Feb 1, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
July 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 18, 2026Material agreement entered, new material financial obligationForm8-K
- Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 5, 2026Results of operations, Regulation FD disclosureForm8-K
- Jul 30, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 30, 2026Results of operations, Regulation FD disclosureForm8-K
- Jun 2, 2026Other material eventsForm8-K
- May 27, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- May 21, 2026Other material eventsForm8-K
- May 14, 2026Shares registered for employeesFormS-8
- May 14, 2026Officer or director change, shareholder voteForm8-K
- May 1, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 1, 2026Results of operations, Regulation FD disclosureForm8-K
- Mar 31, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Mar 31, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Mar 31, 2026Additional annual meeting materialFormDEFA14A
- Mar 31, 2026Annual meeting proxy statementFormDEF 14A
- Mar 17, 2026Material agreement entered, acquisition or disposal of assets, Regulation FD disclosureForm8-K
- Feb 27, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 27, 2026Results of operations, Regulation FD disclosureForm8-K
- Feb 4, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Dec 22, 2025Material agreement entered, other material eventsForm8-K
- Nov 7, 2025Quarterly reportfor the period to Sep 30, 2025Form10-Q
- Nov 7, 2025Results of operations, Regulation FD disclosureForm8-K
- Oct 20, 2025Other material eventsForm8-K
- Aug 27, 2025Filing (amendment)Form144/A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 18, 2026 | 8-K | Material agreement entered, new material financial obligation | Document |
| Nov 5, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 5, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Jul 30, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 30, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Jun 2, 2026 | 8-K | Other material events | Document |
| May 27, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| May 21, 2026 | 8-K | Other material events | Document |
| May 14, 2026 | S-8 | Shares registered for employees | Document |
| May 14, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 1, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 1, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Mar 31, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Mar 31, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Mar 31, 2026 | DEFA14A | Additional annual meeting material | Document |
| Mar 31, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 17, 2026 | 8-K | Material agreement entered, acquisition or disposal of assets, Regulation FD disclosure | Document |
| Feb 27, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 27, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Feb 4, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Dec 22, 2025 | 8-K | Material agreement entered, other material events | Document |
| Nov 7, 2025 | 10-Q | Quarterly reportfor the period to Sep 30, 2025 | Document |
| Nov 7, 2025 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Oct 20, 2025 | 8-K | Other material events | Document |
| Aug 27, 2025 | 144/A | Filing (amendment) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jun 9, 2016.
The full analysis
What do Fulgent Genetics's filings show?
The filings are where every one of Fulgent Genetics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.